

---

# Index

## A

Adjuvant radiation therapy, 55  
American College of Radiology (ACR)  
    Appropriateness Criteria, 128  
Anterolateral thigh musculocutaneous flap, 63  
ARID1A, 26  
Asymptomatic lichen sclerosus, 7

## B

Balanitis xerotica obliterans, 7  
Bilateral palpable inguinal adenopathy, 56  
Biomarkers  
    Ki-67, 23  
    p16<sup>INK4a</sup>, 22  
    p53, 20  
    proliferating cell nuclear antigen (PCNA), 24  
Bleomycin, 57  
Bleomycin, methotrexate, and cisplatin  
    (BMP), 94  
Buschke-Lowenstein tumor, 6

## C

Cancer-specific survival (CSS), 14  
Carbon dioxide (CO<sub>2</sub>) lasers, 35  
Carcinoma in situ (CIS), 7  
Chemotherapy  
    cisplatin, 136  
    combination therapy, 137  
    intravenous/intra-arterial therapy, 139  
    irinotecan and gemcitabine, 138  
    taxane, 138  
    timing considerations, 139–141  
Cigarette smoking, 2  
Circumcision, 35  
Cisplatin, 136  
Clinically node-negative (cN0) patients, 45

Clinical target volume (CTV), 114  
Condyloma acuminatum, 5  
Conventional imaging techniques, 46  
C-reactive protein (CRP), 24  
Cyclin D1, 25  
Cyclooxygenase-2 (COX-2), 5

## D

Diagnostic and Statistical Manual of Mental  
    Disorders of psychiatric illness  
    (DSM III-R), 112  
DNA sequencing techniques, 3  
Doppler ultrasound (US), 15  
Dynamic sentinel node biopsy (DSNB), 17

## E

E-cadherin, 26  
Epidermal growth factor receptor (EGFR), 104  
Erythroplasia of Queyrat, 7, 113  
European Association of Urology (EAU)<sup>®</sup>,  
    83, 96  
European Organization for Research and  
    Treatment of Cancer (EORTC), 99  
External beam radiotherapy, 114

## F

<sup>18</sup>F-fluorodeoxyglucose (FDG), 48  
Fine needle aspiration cytology (FNAC), 47  
Fossa ovalis, 73

## G

Gemcitabine, 138  
General Health Questionnaire (GHQ), 112  
Groin lymphadenectomy, 69

**H**

HDR brachytherapy, 120  
 Hospital Anxiety and Depression Score (HADS), 112  
 Human papillomavirus (HPV), 13, 103

**I**

Imiquimod, 35  
 Indocyanine green (ICG), 17  
 International Cancer Genome Consortium, 20  
 International Penile Advanced Cancer Trial (InPACT), 89, 128  
 International Rare Cancers Initiative (IRCI), 93, 104  
 Irinotecan, 138

**L**

Laparo-endoscopic single-site (LESS) surgery, 76  
 Laser therapies, 35  
 LDR brachytherapy, 115  
 Leukoplakia, 4  
 Lichen sclerosis, 7  
 Lichen sclerosus, 4  
 Lymphadenectomy, 46  
 Lymphoscintigraphy, 46  
 Lymphotropic nanoparticle-enhanced MR imaging, 17

**M**

Magnetic resonance imaging (MRI), 14  
 Matrix metalloproteinase (MMP), 26  
 Meatal stenosis, 124  
 Minimally invasive staging procedures, 46  
 MMP-9 immunoreactivity, 26  
 Moh's Micrographic surgery (MMS), 38

**N**

National Comprehensive Cancer Network [NCCN] guidelines, 83, 96  
 NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) Trial, 144  
 Neoadjuvant chemotherapy, 56, 62, 88  
 Neodymium: yttrium aluminium garnet (Nd:YAG) lasers, 35

**P**

Palliative treatment, 130  
 Partial glans resurfacing (PGR), 37

Pazopanib, 144  
 Pelvic lymph node dissection (PLND)  
   indication, 82  
   radiation therapy, 89  
   surgical technique, 84  
   systemic therapy, for pelvic nodal disease, 87  
   unilateral vs. bilateral PLND, 85  
 Penile cancer  
   biomarkers  
     Ki-67, 23  
     matrix metalloproteinase, 26  
     p16<sup>INK4a</sup>, 22  
     p53, 20  
     proliferating cell nuclear antigen, 24  
 Bowenoid papulosis, 6  
 clinically node positive inguinal field, 60  
 condyloma acuminatum, 5  
 contralateral clinically node negative inguinal field, 61  
 C-reactive protein, 24  
 cyclin D1, 25  
 DVT/PE prophylaxis, 58  
 Erythroplasia of Queyrat and Bowen's Disease, 7  
 giant condyloma acuminatum/Buschke-Lowenstein tumor, 6  
 high-volume lymph node metastasis, 57  
 histologic subtypes, 7  
 HPV-independent pathway, 4  
 indications, for pelvic lymph node dissection, 62  
 lichen sclerosis, 7  
 locally advanced/regionally metastatic disease  
   adjuvant chemotherapy, 94  
   chemoradiotherapy, 101  
   international clinical trial, 104–105  
   multimodal approach, 98–101  
   postoperative radiotherapy, 96  
 lymph node staging  
   FDG-PET/CT, 48  
   risk-adapted approach, 46  
   sentinel node biopsy, 46  
 metastatic lymphatic spread, 16  
 MRI, 14  
 MRI-PET, 17  
 pathophysiology, 3  
 patient position, 59  
 patient surgical decision making, 55  
 PLND (*see* Pelvic lymph node dissection (PLND))  
 postoperative care, 63  
 postoperative complications, 64  
 radiotherapy (*see* Radiotherapy)

- risk factors, 2
  - skin incision, 60
  - unresectable inguinal lymphadenopathy, 56
- Penile-sparing surgery, 34, 35
  - circumcision, 35
  - distal corporectomy/partial penectomy and reconstruction, 40–41
  - glansectomy and reconstruction, 38–40
  - laser therapies, 35
  - Moh's Micrographic surgery, 38
  - partial glans resurfacing, 37
  - topical therapies, 34, 35
  - total glans resurfacing, 36–37
  - wide local excision/partial glansectomy, 38
- Phimosis, 2, 7
- Plesio brachytherapy, 123
- Proliferating cell nuclear antigen (PCNA), 24
- Prostaglandin E2 (PGE2), 5
  
- Q**
- Quality of life (QOL), 14
  
- R**
- Radiotherapy
  - anal canal SCC, 126
  - carcinoma in situ, 113
  - cervical cancer, 126
  - immunotherapy, 141
  - invasive cancer
    - external beam radiotherapy, 113
    - HDR brachytherapy, 120
    - LDR brachytherapy, 114
    - patient selection, 121
    - surface mold plesiotherapy, 121
  - palliative treatment, 130
  - primary tumor, 112
  - regional radiotherapy, 124
  - targeted drugs, 143
  - vulvar cancer, 126
- Retinoblastoma protein (pRb), 3
- Robot-assisted video endoscopic inguinal lymphadenectomy, 75
  
- S**
- Saphenous vein, 77
- Sartorius muscle flap, 63
- Scrotoplasty, 40
- Sentinel LNs (SLNs), 18
- Soft tissue ulceration, 124
- Southwest Oncology Group (SWOG), 98
- Squamous cell carcinoma (SCC), 13
- Surface mold plesiotherapy, 121
  
- T**
- Taxanes, 138
- Tobacco, 2
- Total glans resurfacing (TGR), 36–37
  
- U**
- Ultrasonography, 47
  
- V**
- Video edoscopic inguinal lymphadenectomy
  - anterior working space, 72
  - fossa ovalis, 73
  - inguinal ligament, dissection, 74
  - medial and lateral boundaries, 72
  - packet removal and drain placement, 74
  - patient preparation and position, 70
  - posterior packet division and saphenous vein division, 73
  - room set up, 71
  - saphenofemoral vein dissection and transection, 73
  - trocar placement, 71
- Vincristine, bleomycin, and methotrexate (VBM), 94
- Vulvar cancer, 126